MannKind Corp. (Nasdaq: MNKD) engaged in discussions with the Food and Drug Administration regarding the label for its inhaled insulin Afresa. The stock price fell $1.07 to close at $7.92.
MannKind Discusses Afresa Label
January 05, 2010 at 18:18 PM EST
